



Reprinted
March 4, 2014

ENGROSSED HOUSE BILL No. 1218

DIGEST OF HB 1218 (Updated March 3, 2014 5:15 pm - DI 104)

Citations Affected: IC 12-7; IC 12-23; IC 16-39; IC 35-48; noncode.

Synopsis: Drug treatment and reporting. Expires standards for operation rules concerning prior authorization for a take home supply of opioid treatment medication (current law requires rules to require prior authorization for more than 14 days of medication). Prohibits an opioid treatment program from prescribing, dispensing, or providing more than a seven day supply of opioid treatment medication to a patient to take out of the facility. Requires the division of mental health and addiction (division) to establish certain standards and protocols for opioid treatment programs. Requires an opioid treatment program to follow the standards and protocols adopted by the division for each opioid treatment program patient. Requires the dispenser at an opioid
(Continued next page)

Effective: Upon passage; July 1, 2014.

Davisson, Clere

(SENATE SPONSORS — MILLER PATRICIA, GROOMS)

January 14, 2014, read first time and referred to Committee on Public Health.
January 23, 2014, amended, reported — Do Pass.
January 29, 2014, read second time, amended, ordered engrossed.
January 30, 2014, engrossed. Read third time, passed. Yeas 95, nays 0.

SENATE ACTION

February 4, 2014, read first time and referred to Committee on Judiciary
February 13, 2014, reassigned to Committee on Health and Provider Services.
February 27, 2014, amended, reported favorably — Do Pass.
March 3, 2014, read second time, amended, ordered engrossed.

EH 1218—LS 6952/DI 77



Digest Continued

treatment program to transmit certain information to the division within specified time frames. Provides that the information is subject to federal patient confidentiality regulations. Requires a provider to release certain information from a committed patient's mental health records upon request of a court. Requires that the board of pharmacy adopt a rule requiring a practitioner and a opioid treatment program to check the Indiana scheduled prescription electronic collection and tracking (INSPECT) program in specified circumstances. Requires the division to report on the information collected. Increases the penalty to a Level 6 felony for violations of the central repository for controlled substances data laws. Requires the Indiana professional licensing agency to study the impact of including all prescription drugs in the INSPECT program and sets forth requirements of the study. Requires the legislative council to assign an interim committee to study: (1) the security of the INSPECT program; and (2) whether opioid treatment programs should be prohibited from allowing patients to take home opioid treatment medication. (The introduced version of this bill was prepared by the commission on mental health and addiction.)

EH 1218—LS 6952/DI 77



Reprinted
March 4, 2014

Second Regular Session 118th General Assembly (2014)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in **this style type**, and deletions will appear in ~~this style type~~.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or ~~this style type~~ reconciles conflicts between statutes enacted by the 2013 Regular Session and 2013 First Regular Technical Session of the General Assembly.

ENGROSSED HOUSE BILL No. 1218

A BILL FOR AN ACT to amend the Indiana Code concerning human services.

Be it enacted by the General Assembly of the State of Indiana:

1 SECTION 1. IC 12-7-2-67.5 IS ADDED TO THE INDIANA CODE
2 AS A **NEW** SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
3 1, 2014]: **Sec. 67.5. "Dispense", for purposes of IC 12-23-18-8, has**
4 **the meaning set forth in IC 12-23-18-8(a).**

5 SECTION 2. IC 12-23-18-2.5, AS ADDED BY P.L.116-2008,
6 SECTION 5, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
7 JULY 1, 2014]: Sec. 2.5. (a) An opioid treatment program must
8 periodically and randomly test, including before receiving treatment,
9 a patient for the following during the patient's treatment by the
10 program:

- 11 (1) Methadone.
12 (2) Cocaine.
13 (3) Opiates.
14 (4) Amphetamines.

EH 1218—LS 6952/DI 77



- 1 (5) Barbiturates.
 2 (6) Tetrahydrocannabinol.
 3 (7) Benzodiazepines.
 4 (8) Any other suspected or known drug that may have been
 5 abused by the patient.
 6 (b) If a patient tests positive under a test described in subsection (a)
 7 for:
 8 (1) a controlled substance other than a drug for which the patient
 9 has a prescription or that is part of the patient's treatment plan at
 10 the opioid treatment program; or
 11 (2) an illegal drug other than the drug that is part of the patient's
 12 treatment plan at the opioid treatment program;
 13 the opioid treatment program and the patient must comply with the
 14 requirements under subsection (c).
 15 (c) If a patient tests positive under a test for a controlled substance
 16 or illegal drug that is not allowed under subsection ~~(b)~~; **(a)**, the
 17 following conditions must be met:
 18 (1) The opioid treatment program must refer the patient to the
 19 onsite physician for a clinical evaluation that must be conducted
 20 not more than ten (10) days after the date of the patient's positive
 21 test. The physician shall consult with medical and behavioral staff
 22 to conduct the evaluation. The clinical evaluation must
 23 recommend a remedial action for the patient that may include
 24 discharge from the opioid treatment program or amending the
 25 treatment plan to require a higher level of supervision.
 26 (2) The opioid treatment program may not allow the patient to
 27 take any opioid treatment medications from the treatment facility
 28 until the patient has completed a clinical assessment under
 29 subdivision (1) and has passed a random test. The patient must
 30 report to the treatment facility daily, except when the facility is
 31 closed, until the onsite physician, after consultation with the
 32 medical and behavioral staff, determines that daily treatment is no
 33 longer necessary.
 34 (3) The patient must take a weekly random test until the patient
 35 passes a test under subsection ~~(b)~~; **(a)**.
 36 (d) An opioid treatment program must conduct all tests required
 37 under this section in an observed manner to assure that a false sample
 38 is not provided by the patient.
 39 SECTION 3. IC 12-23-18-5, AS AMENDED BY P.L.116-2008,
 40 SECTION 8, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
 41 JULY 1, 2014]: Sec. 5. (a) The division shall adopt rules under
 42 IC 4-22-2 to establish the following:

EH 1218—LS 6952/DI 77



1 (1) Standards for operation of an opioid treatment program in
 2 Indiana, including the following requirements:

3 (A) An opioid treatment program shall obtain prior
 4 authorization from the division for any patient receiving more
 5 than fourteen (14) days of opioid treatment medications at one
 6 (1) time. **This clause expires June 30, 2014.**

7 (B) Minimum requirements for a licensed physician's regular:
 8 (i) physical presence in the opioid treatment facility; and
 9 (ii) physical evaluation and progress evaluation of each
 10 opioid treatment program patient.

11 (C) Minimum staffing requirements by licensed and
 12 unlicensed personnel.

13 (D) Clinical standards for the appropriate tapering of a patient
 14 on and off of an opioid treatment medication.

15 **Any standard for operation rule previously adopted by the**
 16 **division under this subdivision that allowed an opioid**
 17 **treatment program to obtain prior authorization for opioid**
 18 **treatment medication for any patient in an amount greater**
 19 **than seven (7) days is void.**

20 (2) A requirement that, not later than February 28 of each year, a
 21 current diversion control plan that meets the requirements of 21
 22 CFR Part 291 and 42 CFR Part 8 be submitted for each opioid
 23 treatment facility.

24 (3) Fees to be paid by an opioid treatment program for deposit in
 25 the fund for annual certification under this chapter as described
 26 in section 3 of this chapter.

27 The fees established under this subsection must be sufficient to pay the
 28 cost of implementing this chapter.

29 (b) The division shall conduct an annual onsite visit of each opioid
 30 treatment program facility to assess compliance with this chapter.

31 **(c) An opioid treatment program may not:**

32 **(1) prescribe, dispense, or otherwise provide to any patient**
 33 **more than a seven (7) day supply of opioid treatment**
 34 **medication to take out of the opioid treatment program**
 35 **facility; or**

36 **(2) seek authorization from the division to approve for any**
 37 **patient more than a seven (7) day supply of opioid treatment**
 38 **medication to take out of the opioid treatment program**
 39 **facility at one (1) time.**

40 SECTION 4. IC 12-23-18-7 IS ADDED TO THE INDIANA CODE
 41 AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
 42 1, 2014]: **Sec. 7. (a) The division shall adopt rules under IC 4-22-2**



1 to establish standards and protocols for opioid treatment programs
2 to do the following:

3 (1) Assess new opioid treatment program patients to
4 determine the most effective opioid treatment medications to
5 start the patient's opioid treatment.

6 (2) Ensure that each patient voluntarily chooses maintenance
7 treatment and that relevant facts concerning the use of opioid
8 treatment medications are clearly and adequately explained
9 to the patient.

10 (3) Have appropriate opioid treatment program patients who
11 are receiving methadone for opioid treatment move to
12 receiving other approved opioid treatment medications.

13 (b) An opioid treatment program shall follow the standards and
14 protocols adopted under subsection (a) for each opioid treatment
15 program patient.

16 (c) Subject to subsection (a), an opioid treatment program may
17 use any of the following medications as an alternative for
18 methadone for opioid treatment:

19 (1) Buprenorphine.

20 (2) Buprenorphine combination products containing
21 naloxone.

22 (3) Any other medication that has been approved by:

23 (A) the federal Food and Drug Administration for use in
24 the treatment of opioid addiction; and

25 (B) the division under subsection (e).

26 (d) Before starting a patient on a new opioid treatment
27 medication, the opioid treatment program shall explain to the
28 patient the potential side effects of the new medication.

29 (e) The division may adopt rules under IC 4-22-2 to provide for
30 other medications as alternatives to methadone that may be used
31 under subsection (a).

32 SECTION 5. IC 12-23-18-8 IS ADDED TO THE INDIANA CODE
33 AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
34 1, 2014]: Sec. 8. (a) As used in this section, "dispense" means to
35 deliver a controlled substance to an ultimate user.

36 (b) Subject to the federal patient confidentiality requirements
37 under 42 CFR Part 2, when an opioid treatment program dispenses
38 a controlled substance designated by the Indiana board of
39 pharmacy under IC 35-48-2-5 through 35-48-2-10, the opioid
40 treatment program shall provide the following information upon
41 request from the division:

42 (1) The medications dispensed by the program.



1 **(2) The medication delivery process, which includes whether**
 2 **the medication was in liquid, film, or another form.**

3 **(3) The number of doses dispensed of each medication.**

4 **(4) The dosage quantities for each medication.**

5 **(5) The number of patients receiving take home medications.**

6 **(6) The number of days of supply dispensed.**

7 **(7) Patient demographic information for each medication,**
 8 **including gender, age, and time in treatment.**

9 **(8) The dispenser's United States Drug Enforcement Agency**
 10 **registration number.**

11 **(c) An opioid treatment program is required to provide the**
 12 **information required under this section to the division in a manner**
 13 **prescribed by the division.**

14 **(d) The division shall annually report the information collected**
 15 **under this section to the legislative council in an electronic format**
 16 **under IC 5-14-6 not later than October 1 of each year.**

17 SECTION 6. IC 16-39-2-8 IS AMENDED TO READ AS
 18 FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 8. **(a)** The court may
 19 order the release of the patient's mental health record without the
 20 patient's consent upon the showing of good cause following a hearing
 21 under IC 16-39-3 or in a proceeding under IC 31-30 through IC 31-40
 22 following a hearing held under the Indiana Rules of Trial Procedure.

23 **(b) A provider shall, upon the request of a court that has**
 24 **committed a patient under IC 12-26-7, IC 12-26-8, IC 35-36-2-4, or**
 25 **IC 35-36-3, release to the court any information from the patient's**
 26 **mental health record that is required by the division of state court**
 27 **administration for transmission to NICS (as defined in**
 28 **IC 35-47-2.5-2.5) in accordance with IC 33-24-6-3.**

29 SECTION 7. IC 35-48-7-8.1, AS AMENDED BY P.L.152-2012,
 30 SECTION 14, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
 31 UPON PASSAGE]: Sec. 8.1. **(a)** The board shall provide for a
 32 controlled substance prescription monitoring program that includes the
 33 following components:

34 **(1) Each time a controlled substance designated by the board**
 35 **under IC 35-48-2-5 through IC 35-48-2-10 is dispensed, the**
 36 **dispenser shall transmit to the INSPECT program the following**
 37 **information:**

38 **(A) The controlled substance recipient's name.**

39 **(B) The controlled substance recipient's or the recipient**
 40 **representative's identification number or the identification**
 41 **number or phrase designated by the INSPECT program.**

42 **(C) The controlled substance recipient's date of birth.**



- 1 (D) The national drug code number of the controlled substance
 2 dispensed.
 3 (E) The date the controlled substance is dispensed.
 4 (F) The quantity of the controlled substance dispensed.
 5 (G) The number of days of supply dispensed.
 6 (H) The dispenser's United States Drug Enforcement Agency
 7 registration number.
 8 (I) The prescriber's United States Drug Enforcement Agency
 9 registration number.
 10 (J) An indication as to whether the prescription was
 11 transmitted to the pharmacist orally or in writing.
 12 (K) Other data required by the board.
 13 (2) The information required to be transmitted under this section
 14 must be transmitted **as follows:**
 15 (A) **Before July 1, 2015**, not more than seven (7) days after
 16 the date on which a controlled substance is dispensed.
 17 (B) **Beginning July 1, 2015, and until December 31, 2015,**
 18 **not more than three (3) days after the date on which a**
 19 **controlled substance is dispensed.**
 20 (C) **Beginning January 1, 2016, and thereafter, not more**
 21 **than twenty-four (24) hours after the date on which a**
 22 **controlled substance is dispensed.**
 23 (3) A dispenser shall transmit the information required under this
 24 section by:
 25 (A) uploading to the INSPECT web site;
 26 (B) a computer diskette; or
 27 (C) a CD-ROM disk;
 28 that meets specifications prescribed by the board.
 29 (4) The board may require that prescriptions for controlled
 30 substances be written on a one (1) part form that cannot be
 31 duplicated. However, the board may not apply such a requirement
 32 to prescriptions filled at a pharmacy with a Category II permit (as
 33 described in IC 25-26-13-17) and operated by a hospital licensed
 34 under IC 16-21, or prescriptions ordered for and dispensed to
 35 bona fide enrolled patients in facilities licensed under IC 16-28.
 36 The board may not require multiple copy prescription forms for
 37 any prescriptions written. The board may not require different
 38 prescription forms for any individual drug or group of drugs.
 39 Prescription forms required under this subdivision must be
 40 approved by the Indiana board of pharmacy established by
 41 IC 25-26-13-3.
 42 (5) The costs of the program.



1 (b) This subsection applies only to a retail pharmacy. A pharmacist,
 2 pharmacy technician, or person authorized by a pharmacist to dispense
 3 a controlled substance may not dispense a controlled substance to a
 4 person who is not personally known to the pharmacist, pharmacy
 5 technician, or person authorized by a pharmacist to dispense a
 6 controlled substance unless the person taking possession of the
 7 controlled substance provides documented proof of the person's
 8 identification to the pharmacist, pharmacy technician, or person
 9 authorized by a pharmacist to dispense a controlled substance.

10 SECTION 8. IC 35-48-7-11.1, AS AMENDED BY P.L.84-2010,
 11 SECTION 99, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
 12 UPON PASSAGE]: Sec. 11.1. (a) Information received by the
 13 INSPECT program under section 8.1 of this chapter is confidential.

14 (b) The board shall carry out a program to protect the confidentiality
 15 of the information described in subsection (a). The board may disclose
 16 the information to another person only under subsection (c), (d), or (g).

17 (c) The board may disclose confidential information described in
 18 subsection (a) to any person who is authorized to engage in receiving,
 19 processing, or storing the information.

20 (d) Except as provided in subsections (e) and (f), the board may
 21 release confidential information described in subsection (a) to the
 22 following persons:

23 (1) A member of the board or another governing body that
 24 licenses practitioners and is engaged in an investigation, an
 25 adjudication, or a prosecution of a violation under any state or
 26 federal law that involves a controlled substance.

27 (2) An investigator for the consumer protection division of the
 28 office of the attorney general, a prosecuting attorney, the attorney
 29 general, a deputy attorney general, or an investigator from the
 30 office of the attorney general, who is engaged in:

- 31 (A) an investigation;
 32 (B) an adjudication; or
 33 (C) a prosecution;

34 of a violation under any state or federal law that involves a
 35 controlled substance.

36 (3) A law enforcement officer who is an employee of:

- 37 (A) a local, state, or federal law enforcement agency; or
 38 (B) an entity that regulates controlled substances or enforces
 39 controlled substances rules or laws in another state;

40 that is certified to receive **controlled substance prescription**
 41 **drug** information from the INSPECT program.

42 (4) A practitioner or practitioner's agent certified to receive



- 1 information from the INSPECT program.
- 2 (5) A controlled substance monitoring program in another state
- 3 with which Indiana has established an interoperability agreement.
- 4 (6) The state toxicologist.
- 5 (7) A certified representative of the Medicaid retrospective and
- 6 prospective drug utilization review program.
- 7 (8) A substance abuse assistance program for a licensed health
- 8 care provider who:
- 9 (A) has prescriptive authority under IC 25; and
- 10 (B) is participating in the assistance program.
- 11 (e) Information provided to an individual under:
- 12 (1) subsection (d)(3) is limited to information:
- 13 (A) concerning an individual or proceeding involving the
- 14 unlawful diversion or misuse of a schedule II, III, IV, or V
- 15 controlled substance; and
- 16 (B) that will assist in an investigation or proceeding; and
- 17 (2) subsection (d)(4) may be released only for the purpose of:
- 18 (A) providing medical or pharmaceutical treatment; or
- 19 (B) evaluating the need for providing medical or
- 20 pharmaceutical treatment to a patient.
- 21 (f) Before the board releases confidential information under
- 22 subsection (d), the applicant must be approved by the INSPECT
- 23 program in a manner prescribed by the board.
- 24 (g) The board may release to:
- 25 (1) a member of the board or another governing body that licenses
- 26 practitioners;
- 27 (2) an investigator for the consumer protection division of the
- 28 office of the attorney general, a prosecuting attorney, the attorney
- 29 general, a deputy attorney general, or an investigator from the
- 30 office of the attorney general; or
- 31 (3) a law enforcement officer who is:
- 32 (A) authorized by the state police department to receive ~~the~~
- 33 **type of controlled substance prescription drug** information;
- 34 ~~released;~~ and
- 35 (B) approved by the board to receive the type of information
- 36 released;
- 37 confidential information generated from computer records that
- 38 identifies practitioners who are prescribing or dispensing large
- 39 quantities of a controlled substance.
- 40 (h) The information described in subsection (g) may not be released
- 41 until it has been reviewed by:
- 42 (1) a member of the board who is licensed in the same profession



- 1 as the prescribing or dispensing practitioner identified by the data;
 2 or
 3 (2) the board's designee;
 4 and until that member or the designee has certified that further
 5 investigation is warranted. However, failure to comply with this
 6 subsection does not invalidate the use of any evidence that is otherwise
 7 admissible in a proceeding described in subsection (i).
- 8 (i) An investigator or a law enforcement officer receiving
 9 confidential information under subsection (c), (d), or (g) may disclose
 10 the information to a law enforcement officer or an attorney for the
 11 office of the attorney general for use as evidence in the following:
- 12 (1) A proceeding under IC 16-42-20.
 - 13 (2) A proceeding under any state or federal law that involves a
 14 controlled substance.
 - 15 (3) A criminal proceeding or a proceeding in juvenile court that
 16 involves a controlled substance.
- 17 (j) The board may compile statistical reports from the information
 18 described in subsection (a). The reports must not include information
 19 that identifies any practitioner, ultimate user, or other person
 20 administering a controlled substance. Statistical reports compiled under
 21 this subsection are public records.
- 22 (k) **Except as provided in IC 25-22.5-13**, this section may not be
 23 construed to require a practitioner to obtain information about a patient
 24 from the data base.
- 25 (l) A practitioner is immune from civil liability for an injury, death,
 26 or loss to a person solely due to a practitioner seeking or not seeking
 27 information from the INSPECT program. The civil immunity described
 28 in this subsection does not extend to a practitioner if the practitioner
 29 receives information directly from the INSPECT program and then
 30 negligently misuses this information. This subsection does not apply to
 31 an act or omission that is a result of gross negligence or intentional
 32 misconduct.
- 33 (m) The board may review the records of the INSPECT program. If
 34 the board determines that a violation of the law may have occurred, the
 35 board shall notify the appropriate law enforcement agency or the
 36 relevant government body responsible for the licensure, regulation, or
 37 discipline of practitioners authorized by law to prescribe controlled
 38 substances.
- 39 (n) A practitioner who in good faith discloses information based on
 40 a report from the INSPECT program to a law enforcement agency is
 41 immune from criminal or civil liability. A practitioner that discloses
 42 information to a law enforcement agency under this subsection is



1 presumed to have acted in good faith.
2 SECTION 9. IC 35-48-7-12.1, AS AMENDED BY P.L.42-2011,
3 SECTION 77, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
4 JULY 1, 2014]: Sec. 12.1. (a) The board shall adopt rules under
5 IC 4-22-2 to implement this chapter, including the following:
6 (1) Information collection and retrieval procedures for the
7 INSPECT program, including the controlled substances to be
8 included in the program required under section 8.1 of this chapter.
9 (2) Design for the creation of the data base required under section
10 10.1 of this chapter.
11 (3) Requirements for the development and installation of online
12 electronic access by the board to information collected by the
13 INSPECT program.
14 (4) Identification of emergency situations or other circumstances
15 in which a practitioner may prescribe, dispense, and administer a
16 prescription drug specified in section 8.1 of this chapter without
17 a written prescription or on a form other than a form specified in
18 section 8.1(a)(4) of this chapter.
19 **(5) Requirements for a practitioner and an opioid treatment**
20 **program operating under IC 12-23-18 to check the INSPECT**
21 **program:**
22 **(A) before initially prescribing a controlled substance to a**
23 **patient; and**
24 **(B) periodically during the course of treatment that uses a**
25 **controlled substance.**
26 (b) The board may:
27 (1) set standards for education courses for individuals authorized
28 to use the INSPECT program;
29 (2) identify treatment programs for individuals addicted to
30 controlled substances monitored by the INSPECT program; and
31 (3) work with impaired practitioner associations to provide
32 intervention and treatment.
33 SECTION 10. IC 35-48-7-14 IS AMENDED TO READ AS
34 FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 14. A person who
35 knowingly or intentionally violates this chapter commits a ~~Class A~~
36 ~~misdemeanor.~~ **Level 6 felony.**
37 SECTION 11. IC 35-48-7-16 IS ADDED TO THE INDIANA
38 CODE AS A NEW SECTION TO READ AS FOLLOWS
39 [EFFECTIVE JULY 1, 2014]: **Sec. 16. (a) Before October 1, 2014,**
40 **the Indiana professional licensing agency shall:**
41 **(1) study the impact of including all prescription drugs in the**
42 **INSPECT program; and**



- 1 (2) report the findings to the legislative council in an
2 electronic format under IC 5-14-6.
- 3 **(b) The study under subsection (a) must include the following:**
- 4 **(1) The efficacy of including drugs other than controlled**
5 **substances in the INSPECT program.**
- 6 **(2) Recommended parameters for the inclusion of drugs other**
7 **than controlled substances.**
- 8 **(3) Analysis of any security concerns related to patient and**
9 **provider privacy.**
- 10 **(4) Technology requirements.**
- 11 **(5) Regulatory impact analysis.**
- 12 **(6) Fiscal impact analysis.**
- 13 **(c) The:**
- 14 **(1) state department of health;**
- 15 **(2) office of the secretary of family and social services;**
- 16 **(3) department of homeland security; and**
- 17 **(4) Indiana office of technology (IC 4-13.1-2);**
- 18 shall assist the Indiana professional licensing agency with the study
19 required by this section.
- 20 SECTION 12. [EFFECTIVE JULY 1, 2014] **(a) During the 2014**
21 **interim of the general assembly, the legislative council shall assign**
22 **to an appropriate interim committee the study of the integrity and**
23 **security of the INSPECT program (IC 35-48-7). The interim**
24 **committee shall make findings and recommendations, including**
25 **recommendations to the Indiana professional licensing agency**
26 **established by IC 25-1-5-3 to ensure that data collected by the**
27 **INSPECT program may be used only for lawful purposes.**
- 28 **(b) This SECTION expires January 1, 2015.**
- 29 SECTION 13. [EFFECTIVE UPON PASSAGE] **(a) During the**
30 **2014 interim of the general assembly, the legislative council shall**
31 **assign to an appropriate interim committee the study of whether**
32 **opioid treatment programs should be prohibited from allowing**
33 **patients to take home a multiple day supply of opioid treatment**
34 **medication.**
- 35 **(b) This SECTION expires December 31, 2014.**
- 36 SECTION 14. An emergency is declared for this act.



COMMITTEE REPORT

Mr. Speaker: Your Committee on Public Health, to which was referred House Bill 1218, has had the same under consideration and begs leave to report the same back to the House with the recommendation that said bill be amended as follows:

Page 3, delete lines 12 through 42, begin a new paragraph and insert:

"SECTION 4. IC 35-48-7-8.1, AS AMENDED BY P.L.152-2012, SECTION 14, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE UPON PASSAGE]: Sec. 8.1. (a) The board shall provide for a controlled substance prescription monitoring program that includes the following components:

(1) Each time a controlled substance designated by the board under IC 35-48-2-5 through IC 35-48-2-10 is dispensed, the dispenser shall transmit to the INSPECT program the following information:

- (A) The controlled substance recipient's name.
- (B) The controlled substance recipient's or the recipient representative's identification number or the identification number or phrase designated by the INSPECT program.
- (C) The controlled substance recipient's date of birth.
- (D) The national drug code number of the controlled substance dispensed.
- (E) The date the controlled substance is dispensed.
- (F) The quantity of the controlled substance dispensed.
- (G) The number of days of supply dispensed.
- (H) The dispenser's United States Drug Enforcement Agency registration number.
- (I) The prescriber's United States Drug Enforcement Agency registration number.
- (J) An indication as to whether the prescription was transmitted to the pharmacist orally or in writing.
- (K) Other data required by the board.

(2) The information required to be transmitted under this section must be transmitted not more than seven (7) days after the date on which a controlled substance is dispensed. **However, notwithstanding any other provision of this section, beginning:**

- (A) July 1, 2015, the information required to be transmitted under this section must be transmitted not more than three (3) days after the date on which a controlled substance is dispensed; and**



(B) January 1, 2016, the information required to be transmitted under this section must be transmitted not more than twenty-four (24) hours after the date on which a controlled substance is dispensed.

(3) A dispenser shall transmit the information required under this section by:

- (A) uploading to the INSPECT web site;
- (B) a computer diskette; or
- (C) a CD-ROM disk;

that meets specifications prescribed by the board.

(4) The board may require that prescriptions for controlled substances be written on a one (1) part form that cannot be duplicated. However, the board may not apply such a requirement to prescriptions filled at a pharmacy with a Category II permit (as described in IC 25-26-13-17) and operated by a hospital licensed under IC 16-21, or prescriptions ordered for and dispensed to bona fide enrolled patients in facilities licensed under IC 16-28. The board may not require multiple copy prescription forms for any prescriptions written. The board may not require different prescription forms for any individual drug or group of drugs. Prescription forms required under this subdivision must be approved by the Indiana board of pharmacy established by IC 25-26-13-3.

(5) The costs of the program.

(b) This subsection applies only to a retail pharmacy. A pharmacist, pharmacy technician, or person authorized by a pharmacist to dispense a controlled substance may not dispense a controlled substance to a person who is not personally known to the pharmacist, pharmacy technician, or person authorized by a pharmacist to dispense a controlled substance unless the person taking possession of the controlled substance provides documented proof of the person's identification to the pharmacist, pharmacy technician, or person authorized by a pharmacist to dispense a controlled substance.

SECTION 5. IC 35-48-7-11.1, AS AMENDED BY P.L.84-2010, SECTION 99, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE UPON PASSAGE]: Sec. 11.1. (a) Information received by the INSPECT program under section 8.1 of this chapter is confidential.

(b) The board shall carry out a program to protect the confidentiality of the information described in subsection (a). The board may disclose the information to another person only under subsection (c), (d), or (g).

(c) The board may disclose confidential information described in subsection (a) to any person who is authorized to engage in receiving,



processing, or storing the information.

(d) Except as provided in subsections (e) and (f), the board may release confidential information described in subsection (a) to the following persons:

(1) A member of the board or another governing body that licenses practitioners and is engaged in an investigation, an adjudication, or a prosecution of a violation under any state or federal law that involves a controlled substance.

(2) An investigator for the consumer protection division of the office of the attorney general, a prosecuting attorney, the attorney general, a deputy attorney general, or an investigator from the office of the attorney general, who is engaged in:

- (A) an investigation;
- (B) an adjudication; or
- (C) a prosecution;

of a violation under any state or federal law that involves a controlled substance.

(3) A law enforcement officer who is an employee of:

- (A) a local, state, or federal law enforcement agency; or
- (B) an entity that regulates controlled substances or enforces controlled substances rules or laws in another state;

that is certified to receive **controlled substance prescription drug** information from the INSPECT program.

(4) A practitioner or practitioner's agent certified to receive information from the INSPECT program.

(5) A controlled substance monitoring program in another state with which Indiana has established an interoperability agreement.

(6) The state toxicologist.

(7) A certified representative of the Medicaid retrospective and prospective drug utilization review program.

(8) A substance abuse assistance program for a licensed health care provider who:

- (A) has prescriptive authority under IC 25; and
- (B) is participating in the assistance program.

(e) Information provided to an individual under:

(1) subsection (d)(3) is limited to information:

- (A) concerning an individual or proceeding involving the unlawful diversion or misuse of a schedule II, III, IV, or V controlled substance; and
- (B) that will assist in an investigation or proceeding; and

(2) subsection (d)(4) may be released only for the purpose of:

- (A) providing medical or pharmaceutical treatment; or



(B) evaluating the need for providing medical or pharmaceutical treatment to a patient.

(f) Before the board releases confidential information under subsection (d), the applicant must be approved by the INSPECT program in a manner prescribed by the board.

(g) The board may release to:

(1) a member of the board or another governing body that licenses practitioners;

(2) an investigator for the consumer protection division of the office of the attorney general, a prosecuting attorney, the attorney general, a deputy attorney general, or an investigator from the office of the attorney general; or

(3) a law enforcement officer who is:

(A) authorized by the state police department to receive ~~the type of~~ **controlled substance prescription drug** information; ~~released;~~ and

(B) approved by the board to receive the type of information released;

confidential information generated from computer records that identifies practitioners who are prescribing or dispensing large quantities of a controlled substance.

(h) The information described in subsection (g) may not be released until it has been reviewed by:

(1) a member of the board who is licensed in the same profession as the prescribing or dispensing practitioner identified by the data;

or

(2) the board's designee;

and until that member or the designee has certified that further investigation is warranted. However, failure to comply with this subsection does not invalidate the use of any evidence that is otherwise admissible in a proceeding described in subsection (i).

(i) An investigator or a law enforcement officer receiving confidential information under subsection (c), (d), or (g) may disclose the information to a law enforcement officer or an attorney for the office of the attorney general for use as evidence in the following:

(1) A proceeding under IC 16-42-20.

(2) A proceeding under any state or federal law that involves a controlled substance.

(3) A criminal proceeding or a proceeding in juvenile court that involves a controlled substance.

(j) The board may compile statistical reports from the information described in subsection (a). The reports must not include information



that identifies any practitioner, ultimate user, or other person administering a controlled substance. Statistical reports compiled under this subsection are public records.

(k) **Except as provided in IC 25-22.5-13**, this section may not be construed to require a practitioner to obtain information about a patient from the data base.

(l) A practitioner is immune from civil liability for an injury, death, or loss to a person solely due to a practitioner seeking or not seeking information from the INSPECT program. The civil immunity described in this subsection does not extend to a practitioner if the practitioner receives information directly from the INSPECT program and then negligently misuses this information. This subsection does not apply to an act or omission that is a result of gross negligence or intentional misconduct.

(m) The board may review the records of the INSPECT program. If the board determines that a violation of the law may have occurred, the board shall notify the appropriate law enforcement agency or the relevant government body responsible for the licensure, regulation, or discipline of practitioners authorized by law to prescribe controlled substances.

(n) A practitioner who in good faith discloses information based on a report from the INSPECT program to a law enforcement agency is immune from criminal or civil liability. A practitioner that discloses information to a law enforcement agency under this subsection is presumed to have acted in good faith."

Page 4, delete lines 1 through 13, begin a new paragraph and insert:
"SECTION 6. IC 35-48-7-14 IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 14. A person who knowingly or intentionally violates this chapter commits a ~~Class A misdemeanor~~. **Level 6 felony**."

Page 4, line 22, after "substances." insert "**However, the board shall take into account that a dispenser does not collect the same information for a noncontrolled substance prescription and a controlled substance prescription, and the board may not require a pharmacy to collect additional information and submit information for a noncontrolled substance prescription unless the information is typically collected by a dispenser.**"

Page 4, line 24, delete "January" and insert "**July**".

Page 4, between lines 28 and 29, begin a new paragraph and insert:
"**(c) Notwithstanding any other provision of this chapter, beginning July 1, 2015, the information required to be transmitted under this section must be transmitted not more than three (3)**



days after the date on which a prescription drug is dispensed.

(d) Notwithstanding any other provision of this chapter, beginning January 1, 2016, the information required to be transmitted under this section must be transmitted not more than twenty-four (24) hours after the date on which a prescription drug is dispensed."

Page 4, line 29, delete "(c)" and insert "(e)".

Page 4, between lines 33 and 34, begin a new paragraph and insert:

"(f) This section does not apply to a facility licensed under IC 16-28 or a hospital licensed under IC 16-21 that is not required to submit prescription information under section 8.1(a)(4) of this chapter."

Renumber all SECTIONS consecutively.

and when so amended that said bill do pass.

(Reference is to HB 1218 as introduced.)

CLERE, Chair

Committee Vote: yeas 10, nays 0.

HOUSE MOTION

Mr. Speaker: I move that House Bill 1218 be amended to read as follows:

Page 1, line 11, delete "but least addictive".

Page 1, line 12, delete "drugs" and insert "**medications**".

Page 1, between lines 12 and 13, begin a new line block indented and insert:

"(2) Ensure that each patient voluntarily chooses maintenance treatment and that relevant facts concerning the use of opioid treatment medications are clearly and adequately explained to the patient."

Page 1, line 13, delete "(2)" and insert "(3)".

Page 2, line 1, delete "less addictive" and insert "**other approved**".

Page 2, line 1, delete "drugs." and insert "**medications**".

Page 2, delete lines 2 through 5.

Page 2, line 10, delete "drugs" and insert "**medications**".

Page 2, line 10, delete "a less addictive replacement" and insert "**an alternative**".

Page 2, line 15, delete "drug" and insert "**medication**".

EH 1218—LS 6952/DI 77



Page 2, line 19, delete "drug," and insert "**medication,**".

Page 2, line 21, delete "drug." and insert "**medication.**".

Page 2, line 23, delete "drugs that are less addictive than" and insert "**medications as alternatives to**".

Page 2, line 30, delete "a controlled substance designated by" and insert "**an opioid treatment program dispenses a controlled substance designated by the Indiana board of pharmacy under IC 35-48-2-5 through 35-48-2-10, the opioid treatment program shall provide the following information upon request from the division:**

- (1) **The medications dispensed by the program.**
- (2) **The medication delivery process, which includes whether the medication was in liquid, film, or another form.**
- (3) **The number of doses dispensed of each medication.**
- (4) **The dosage quantities for each medication.**
- (5) **The number of patients receiving take home medications.**
- (6) **The number of days of supply dispensed.**
- (7) **Patient demographic information for each medication, including gender, age, and time in treatment.**
- (8) **The dispenser's United States Drug Enforcement Agency registration number."**

Page 2, delete lines 31 through 42.

Page 3, delete lines 1 through 4.

Page 7, between lines 29 and 30, begin a new paragraph and insert:
 "SECTION 5. IC 35-48-7-12.1, AS AMENDED BY P.L.42-2011, SECTION 77, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 12.1. (a) The board shall adopt rules under IC 4-22-2 to implement this chapter, including the following:

- (1) Information collection and retrieval procedures for the INSPECT program, including the controlled substances to be included in the program required under section 8.1 of this chapter.
- (2) Design for the creation of the data base required under section 10.1 of this chapter.
- (3) Requirements for the development and installation of online electronic access by the board to information collected by the INSPECT program.
- (4) Identification of emergency situations or other circumstances in which a practitioner may prescribe, dispense, and administer a prescription drug specified in section 8.1 of this chapter without a written prescription or on a form other than a form specified in section 8.1(a)(4) of this chapter.
- (5) **Requirements for a practitioner and an opioid treatment**



program operating under IC 12-23-18 to check the INSPECT program:

(A) before initially prescribing a controlled substance to a patient; and

(B) periodically during the course of treatment that uses a controlled substance.

(b) The board may:

(1) set standards for education courses for individuals authorized to use the INSPECT program;

(2) identify treatment programs for individuals addicted to controlled substances monitored by the INSPECT program; and

(3) work with impaired practitioner associations to provide intervention and treatment."

Page 8, between lines 30 and 31, begin a new paragraph and insert:

"(g) Before January 1, 2015, the Indiana professional licensing agency shall study and analyze the integrity and security of the INSPECT program concerning all controlled substances required to be reported to the INSPECT program. Notwithstanding any other provision of this section, if the Indiana professional licensing agency is unable to certify the integrity and security of the INSPECT program before January 1, 2015, the board may not accept noncontrolled substance prescription information or require the submission of noncontrolled substance prescription information until the Indiana professional licensing agency certifies to the board the integrity and security of the INSPECT program.

SECTION 8. [EFFECTIVE JULY 1, 2014] **(a) During the 2014 interim of the general assembly, the health finance commission (IC 2-5-23) shall study the integrity and security of the INSPECT program (IC 35-48-7). The commission shall make findings and recommendations, including recommendations to the Indiana professional licensing agency established by IC 25-1-5-3 to ensure that data collected by the INSPECT program may be used only for lawful purposes.**

(b) This SECTION expires January 1, 2015."

Renumber all SECTIONS consecutively.

(Reference is to HB 1218 as printed January 24, 2014.)

CLERE



COMMITTEE REPORT

Madam President: The Senate Committee on Health and Provider Services, to which was referred House Bill No. 1218, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill be AMENDED as follows:

Page 1, between lines 4 and 5, begin a new paragraph and insert:

"SECTION 2. IC 12-23-18-2.5, AS ADDED BY P.L.116-2008, SECTION 5, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 2.5. (a) An opioid treatment program must periodically and randomly test, including before receiving treatment, a patient for the following during the patient's treatment by the program:

- (1) Methadone.
- (2) Cocaine.
- (3) Opiates.
- (4) Amphetamines.
- (5) Barbiturates.
- (6) Tetrahydrocannabinol.
- (7) Benzodiazepines.
- (8) Any other suspected or known drug that may have been abused by the patient.

(b) If a patient tests positive under a test described in subsection (a) for:

- (1) a controlled substance other than a drug for which the patient has a prescription or that is part of the patient's treatment plan at the opioid treatment program; or
- (2) an illegal drug other than the drug that is part of the patient's treatment plan at the opioid treatment program;

the opioid treatment program and the patient must comply with the requirements under subsection (c).

(c) If a patient tests positive under a test for a controlled substance or illegal drug that is not allowed under subsection ~~(b)~~; **(a)**, the following conditions must be met:

- (1) The opioid treatment program must refer the patient to the onsite physician for a clinical evaluation that must be conducted not more than ten (10) days after the date of the patient's positive test. The physician shall consult with medical and behavioral staff to conduct the evaluation. The clinical evaluation must recommend a remedial action for the patient that may include discharge from the opioid treatment program or amending the



treatment plan to require a higher level of supervision.

(2) The opioid treatment program may not allow the patient to take any opioid treatment medications from the treatment facility until the patient has completed a clinical assessment under subdivision (1) and has passed a random test. The patient must report to the treatment facility daily, except when the facility is closed, until the onsite physician, after consultation with the medical and behavioral staff, determines that daily treatment is no longer necessary.

(3) The patient must take a weekly random test until the patient passes a test under subsection ~~(b)~~: **(a)**.

(d) An opioid treatment program must conduct all tests required under this section in an observed manner to assure that a false sample is not provided by the patient.

SECTION 3. IC 12-23-18-5, AS AMENDED BY P.L.116-2008, SECTION 8, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 5. (a) The division shall adopt rules under IC 4-22-2 to establish the following:

(1) Standards for operation of an opioid treatment program in Indiana, including the following requirements:

(A) An opioid treatment program shall obtain prior authorization from the division for any patient receiving more than ~~fourteen (14)~~ **seven (7)** days of opioid treatment medications at one (1) time.

(B) Minimum requirements for a licensed physician's regular:
 (i) physical presence in the opioid treatment facility; and
 (ii) physical evaluation and progress evaluation of each opioid treatment program patient.

(C) Minimum staffing requirements by licensed and unlicensed personnel.

(D) Clinical standards for the appropriate tapering of a patient on and off of an opioid treatment medication.

(2) A requirement that, not later than February 28 of each year, a current diversion control plan that meets the requirements of 21 CFR Part 291 and 42 CFR Part 8 be submitted for each opioid treatment facility.

(3) Fees to be paid by an opioid treatment program for deposit in the fund for annual certification under this chapter as described in section 3 of this chapter.

The fees established under this subsection must be sufficient to pay the cost of implementing this chapter.

(b) The division shall conduct an annual onsite visit of each opioid



treatment program facility to assess compliance with this chapter."

Page 3, line 8, delete ":" and insert **"legislative council in an electronic format under IC 5-14-6 not later than October 1 of each year."**

Page 3, delete lines 9 through 10, begin a new paragraph and insert:

"SECTION 4. IC 16-39-2-8 IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 8. **(a)** The court may order the release of the patient's mental health record without the patient's consent upon the showing of good cause following a hearing under IC 16-39-3 or in a proceeding under IC 31-30 through IC 31-40 following a hearing held under the Indiana Rules of Trial Procedure.

(b) A provider shall, upon the request of a court that has committed a patient under IC 12-26-7, IC 12-26-8, IC 35-36-2-4, or IC 35-36-3, release to the court any information from the patient's mental health record that is required by the division of state court administration for transmission to NICS (as defined in IC 35-47-2.5-2.5) in accordance with IC 33-24-6-3."

Page 3, line 38, after "transmitted" insert **"as follows:**

(A) Before July 1, 2015,"

Page 3, line 39, delete "However,".

Page 3, delete lines 40 through 42, begin a new line double block indented and insert:

"(B) Beginning July 1, 2015, and until December 31, 2015, not more than three (3) days after the date on which a controlled substance is dispensed.

(C) Beginning January 1, 2016, and thereafter, not more than twenty-four (24) hours after the date on which a controlled substance is dispensed."

Page 4, delete lines 1 through 7.

Page 8, line 24, delete "Notwithstanding any other provision of this" and insert **"Before October 1, 2014, the Indiana professional licensing agency shall:**

(1) study the impact of including all prescription drugs in the INSPECT program; and

(2) report the findings to the legislative council in an electronic format under IC 5-14-6.

(b) The study under subsection (a) must include the following:

(1) The efficacy of including drugs other than controlled substances in the INSPECT program.

(2) Recommended parameters for the inclusion of drugs other than controlled substances.

(3) Analysis of any security concerns related to patient and



provider privacy.

(4) Technology requirements.

(5) Regulatory impact analysis.

(6) Fiscal impact analysis.

(c) The:

(1) state department of health;

(2) office of the secretary of family and social services;

(3) department of homeland security; and

(4) Indiana office of technology (IC 4-13.1-2);

shall assist the Indiana professional licensing agency with the study required by this section."

Page 8, delete lines 25 through 42.

Page 9, delete lines 1 through 30.

Page 9, line 32, delete "health finance commission" and insert "legislative council shall assign to an appropriate interim committee the".

Page 9, line 33, delete "(IC 2-5-23) shall".

Page 9, line 33, after "study" insert "of".

Page 9, line 34, delete "commission" and insert "interim committee".

Renumber all SECTIONS consecutively.

and when so amended that said bill do pass.

(Reference is to HB 1218 as reprinted January 30, 2014.)

MILLER PATRICIA, Chairperson

Committee Vote: Yeas 11, Nays 0.

SENATE MOTION

Madam President: I move that Engrossed House Bill 1218 be amended to read as follows:

Page 3, line 5, reset in roman "fourteen (14)".

Page 3, line 5, delete "seven (7)".

Page 3, line 6, after "time." insert "**This clause expires June 30, 2014.**".

Page 3, between lines 14 and 15, begin a new line block indented and insert:

"Any standard for operation rule previously adopted by the division under this subdivision that allowed an opioid



treatment program to obtain prior authorization for opioid treatment medication for any patient in an amount greater than seven (7) days is void."

Page 3, between lines 25 and 26, begin a new paragraph and insert:

"(c) An opioid treatment program may not:

(1) prescribe, dispense, or otherwise provide to any patient more than a seven (7) day supply of opioid treatment medication to take out of the opioid treatment program facility; or

(2) seek authorization from the division to approve for any patient more than a seven (7) day supply of opioid treatment medication to take out of the opioid treatment program facility at one (1) time."

(Reference is to EHB 1218 as printed February 28, 2014.)

MILLER PATRICIA

SENATE MOTION

Madam President: I move that Engrossed House Bill 1218 be amended to read as follows:

Page 11, between lines 14 and 15, begin a new paragraph and insert:

"SECTION 13. [EFFECTIVE UPON PASSAGE] (a) During the 2014 interim of the general assembly, the legislative council shall assign to an appropriate interim committee the study of whether opioid treatment programs should be prohibited from allowing patients to take home a multiple day supply of opioid treatment medication.

(b) This SECTION expires December 31, 2014."

Renumber all SECTIONS consecutively.

(Reference is to EHB 1218 as printed February 28, 2014.)

LANANE

